| Identification | Back Directory | [Name]
4(3H)-Pyrimidinone, 2-[2-[4-[4-chloro-3-(trifluoromethyl)phenoxy]phenyl]ethoxy]-5-(5-pyrimidinylmethyl)- | [CAS]
1380426-95-8 | [Synonyms]
GSK2647544
4(3H)-Pyrimidinone, 2-[2-[4-[4-chloro-3-(trifluoromethyl)phenoxy]phenyl]ethoxy]-5-(5-pyrimidinylmethyl)- | [Molecular Formula]
C24H18ClF3N4O3 | [MOL File]
1380426-95-8.mol | [Molecular Weight]
502.87 |
| Chemical Properties | Back Directory | [density ]
1.40±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 100 mg/mL (198.86 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
7.87±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
GSK2647544 is an orally available, selective inhibitor of Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived macrophages[1]. | [References]
[1] Wu K, et al. Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers?. Int J Clin Pharmacol Ther. 2016;54(12):935-949. DOI:10.5414/CP202565 |
|
|